CHUGAI PHARMACEUTICAL CO., LTD The safety profile was consistent with previous overseas studies.
R/R FL is a disease that repeatedly recurs and is difficult to cure, and new treatment strategies are required. We are very pleased that bispecific antibody mosunetuzumab achieved CRR and showed promising results for remission. We will continue efforts to apply for the approval of mosunetuzumab in
Chugai will file a new drug application in
About Japanese Phase I study for mosunetuzumab
This study is a Japanese phase I clinical study to evaluate the efficacy and safety of mosunetuzumab in a dose-escalation cohort and in an expansion cohort for patients with R/R FL who have previously received two or more systemic therapies. 19 patients were enrolled in the expansion cohort. The primary endpoint was CRR. Key secondary endpoints included overall response rate, progression-free survival, and duration of response.
About mosunetuzumab
Mosunetuzumab is a CD20xCD3 T cell-engaging bispecific antibody designed to target CD20 on B cells and CD3 on T cells. Mosunetuzumab is expected to activate the immune system through cytotoxic T cells and have antitumor effects on CD20 expressed tumor cells. Mosunetuzumab is currently being developed with intravenous and subcutaneous formulations for the treatment of R/R FL and R/R aggressive B-cell non-Hodgkin lymphoma.
About follicular lymphoma
FL is a type of lymphoma that occurs when B lymphocytes, a type of white blood cell, become cancerous. At diagnosis, 70-85% of patients reach an advanced stage1. Generally, the progression is slow, and chemotherapy is initially effective, but recurrences occur repeatedly in many cases. Repeated recurrences can make it difficult for existing treatments to be effective, and new highly effective treatments are expected. In
Contact:
Tel: +81-3-3273-0881
Email: pr@chugai-pharm.co.jp
Tel: +81-3-3273-0554
Email: ir@chugai-pharm.co.jp
(C) 2024 Electronic News Publishing, source
